Menu

Board of Directors

Dror Ben-Asher , Chairman

Dror Ben-Asher co-founded RedHill and serves as the Company's CEO and Chairman, bringing extensive managerial and transactional expertise. He was previously with ProSeed Capital, a European corporate finance boutique. Dror is a graduate of the University of Oxford (M.Jur.) and completed his LL.M. studies at Harvard University. At Harvard, Dror was also a Fulbright Scholar focusing on the pharmaceutical industry and markets, an Olin Fellow for Law, Economics and Business, and an Economics Teaching Fellow at Harvard’s Economics Department. Dror received an LL.B. with distinction (First Class Honors) from the University of Leicester.

Eric Swenden , Director

Mr. Swenden had a long and successful career in finance and company management. He held various senior positions in companies including Vandemoortele Food Group and General Bank (Fortis) and Lifeline Scientific (current).

Kenneth Reed MD , Director

Dr. Reed is an experienced physician and director. He is currently with Kenneth Reed M.D. P.C. (Dermatologist) and Minerva Biotechnologies. Dr. Reed was also a Clinical Investigator for companies including Amgen, Astellas and Centocor (J&J). He is a graduate of Harvard Medical School (residency in dermatology), Thomas Jefferson University Hospital (medical internship), College of Medicine and Dentistry of New Jersey (M.D.) and Brown University (B.A.).

Rick D. Scruggs , Director

With more than 25 years of experience in the pharmaceutical industry, Mr. Scruggs brings extensive knowledge in commercial operations and business development. He most recently served as executive vice president of business development at Salix Pharmaceuticals, Inc. (“Salix”), until its acquisition by Valeant Pharmaceuticals International, Inc. (now Bausch Health Companies Inc.). Mr. Scruggs joined Salix in 2000, after working at Oclassen Pharmaceuticals, Inc. and Watson Pharmaceuticals, Inc. At Salix, Mr. Scruggs helped build the company’s commercial organization, serving in various sales and commercial trade-related positions. He was appointed executive vice president in 2011 and was responsible for all business development activities as well as the worldwide distribution of Salix’s innovative products and intellectual property. Mr. Scruggs also served as chairperson of the board of directors of Oceana Therapeutics, Salix’s European subsidiary.

Shmuel Cabilly PhD , Director

Mr. Cabilly is a highly regarded scientist and an experienced director. He was previously with several companies including Ethrog Biotech (Co-Founder and Chief Scientist) which was sold to Invitrogen. He graduated from the Hebrew University (Ph.D., Immunology), and was a Post-Doctoral fellow at the City of Hope Research Institute heading a joint City of Hope/Genentech project where he developed a new technology for recombinant antibody production.

Alla Felder, Director

Ms. Felder is a CPA, business and financial advisor with 20 years’ financial management experience. Ms. Felder currently serves as a Director in numerous publicly listed leading Israeli companies across several industries. She also served on the board of Neuroderm Ltd., leading up to its acquisition by Mitsubishi Tanabe Pharma Corporation in 2017. Ms. Felder is a business and financial advisor and currently serves as an external CFO for several technology companies and is also a lecturer in the College of Management Academic Studies Division. Between 1997 and 2010 Ms. Felder was with PriceWaterhouseCoopres where she served in her last role as a Senior Manager.

Ofer Tsimchi , Director

Mr. Tsimchi has many years of business experience in various executive positions. Mr. Tsimchi is the co-founder and manager of Danbar Group and serves as the Chairman of Polysack (TASE: PLSK). Mr. Tsimchi served as a board member of several companies including, among others, Tefron (TASE:TFRN) and Kapro Industries Ltd. (present). Mr. Tsimchi holds a B.Sc. in Economics and Agriculture from the Hebrew University of Jerusalem.

Giuseppe Cipriano, Director

Mr. Giuseppe Cipriano is the Chief Operating Officer at Cosmo Pharmaceuticals. He has served in various roles at Cosmo over the past 19 years, including supervising operations, finance, administration, manufacturing, business relations with drug suppliers and licensees. In 2007, Mr. Cipriano played a lead role in taking Cosmo public on the SIX Swiss Stock Exchange and served as a board member of Cosmo’s affiliates until 2015. Mr. Giuseppe, has also served in various executive roles including managing director of Gianfranco Ferrè S.p.A. and Gianfranco Ferrè US Holding, managing director of Cordara S.p.A. and Ecor Impianti S.r.l., and as vice president in the Public Administration Inland Revenue Department in Milan, Italy.

Nicolas Weinstein , Director

Mr. Weinstein has served as Managing Director of Water Bear Investments LLC since January 2017 and also leads the healthcare and venture investments of EMC2 Fund Ltd. and its partnership interests in Olive Tree Ventures Limited Partnership (Israel) and Puma Bioventures (a U.S. biotech fund). Mr. Weinstein previously served as country head in Chile for Abbott Laboratories / CFR Pharmaceuticals and also held VP Business Development and VP Marketing & Sales positions at CFR Pharmaceuticals. Mr. Weinstein holds an M.Sc. in Finance from Universidad Adolfo Ibanez (Chile) and an MBA from the Kellogg School of Management (2012).